Thompson Siegel & Walmsley LLC Grows Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Thompson Siegel & Walmsley LLC boosted its position in HCA Healthcare, Inc. (NYSE:HCA) by 5.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 16,028 shares of the company’s stock after acquiring an additional 800 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in HCA Healthcare were worth $6,514,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Trustmark National Bank Trust Department lifted its stake in HCA Healthcare by 17.9% during the third quarter. Trustmark National Bank Trust Department now owns 5,819 shares of the company’s stock worth $2,365,000 after purchasing an additional 883 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of HCA Healthcare by 12.8% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 120,149 shares of the company’s stock valued at $48,832,000 after buying an additional 13,618 shares during the last quarter. King Luther Capital Management Corp acquired a new stake in shares of HCA Healthcare during the 3rd quarter worth approximately $248,000. Cornerstone Advisors LLC grew its stake in HCA Healthcare by 4.4% during the 3rd quarter. Cornerstone Advisors LLC now owns 14,300 shares of the company’s stock worth $5,812,000 after buying an additional 600 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in shares of HCA Healthcare by 2.4% during the third quarter. First Horizon Advisors Inc. now owns 1,532 shares of the company’s stock valued at $623,000 after acquiring an additional 36 shares during the period. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Oppenheimer upped their target price on shares of HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a research report on Monday, October 28th. Wolfe Research upgraded HCA Healthcare to a “strong-buy” rating in a research report on Thursday, August 29th. Truist Financial raised their price objective on shares of HCA Healthcare from $390.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, August 19th. Royal Bank of Canada raised their price objective on HCA Healthcare from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Friday, August 23rd. Finally, Barclays dropped their price target on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $385.00.

HCA Healthcare Price Performance

Shares of HCA opened at $332.22 on Friday. The firm has a market cap of $84.15 billion, a PE ratio of 14.92, a PEG ratio of 1.29 and a beta of 1.68. The firm’s 50 day moving average price is $380.80 and its 200 day moving average price is $357.94. The company has a debt-to-equity ratio of 48.71, a quick ratio of 1.00 and a current ratio of 1.12. HCA Healthcare, Inc. has a twelve month low of $245.84 and a twelve month high of $417.14.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be paid a dividend of $0.66 per share. The ex-dividend date is Friday, December 13th. This represents a $2.64 annualized dividend and a yield of 0.79%. HCA Healthcare’s payout ratio is 11.85%.

Insider Activity

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the sale, the insider now directly owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the sale, the executive vice president now directly owns 29,678 shares in the company, valued at approximately $11,438,494.76. The trade was a 21.97 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,155 shares of company stock valued at $5,608,990. 1.60% of the stock is owned by company insiders.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.